Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01-12-2016 | Review

Nerve growth factor: role in growth, differentiation and controlling cancer cell development

Authors: Luigi Aloe, Maria Luisa Rocco, Bijorn Omar Balzamino, Alessandra Micera

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Login to get access

Abstract

Recent progress in the Nerve Growth Factor (NGF) research has shown that this factor acts not only outside its classical domain of the peripheral and central nervous system, but also on non-neuronal and cancer cells. This latter observation has led to divergent hypothesis about the role of NGF, its specific distribution pattern within the tissues and its implication in induction as well as progression of carcinogenesis. Moreover, other recent studies have shown that NGF has direct clinical relevance in certain human brain neuron degeneration and a number of human ocular disorders. These studies, by suggesting that NGF is involved in a plethora of physiological function in health and disease, warrant further investigation regarding the true role of NGF in carcinogenesis. Based on our long-lasting experience in the physiopathology of NGF, we aimed to review previous and recent in vivo and in vitro NGF studies on tumor cell induction, progression and arrest. Overall, these studies indicate that the only presence of NGF is unable to generate cell carcinogenesis, both in normal neuronal and non-neuronal cells/tissues. However, it cannot be excluded the possibility that the co-expression of NGF and pro-carcinogenic molecules might open to different consequence. Whether NGF plays a direct or an indirect role in cell proliferation during carcinogenesis remains to demonstrate.
Literature
1.
Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951;116:321–61.CrossRefPubMed
2.
3.
Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci. 1992;15:323–31.CrossRefPubMed
4.
Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217–12.CrossRefPubMed
5.
Fischer W, Wictorin K, Bjorklund A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329:65–8.CrossRefPubMed
6.
Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of human brain. Brain Res Rev. 1998;27:1–39.CrossRefPubMed
7.
Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol. 2002;50:393–413.CrossRefPubMed
8.
Apfel SC, Arezzo JC, Brownlee M, et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994;634:7–12.CrossRefPubMed
9.
Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF study group. Neurology. 1998;51:695–702.CrossRefPubMed
10.
Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs. 2014;28:275–83.CrossRefPubMed
11.
Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338:1174–80.CrossRefPubMed
12.
Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci U S A. 2009;106:13469–74.CrossRefPubMedPubMedCentral
13.
Lambiase A, Coassin M, Tirassa P, et al. Nerve growth factor eye drops improve visual acuity and electro functional activity in age-related macular degeneration: a case report. Ann Ist Super Sanita. 2009;45:439–42.PubMed
14.
Rocco ML, Balzamino BO, Petrocchi Passeri P, et al. Effect of purified murine NGF on isolated photoreceptors of a rodent developing retinitis pigmentosa. PLoS One. 2015;10, e0124810.CrossRefPubMedPubMedCentral
15.
Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol. 1991;30:625–36.CrossRefPubMed
16.
Ferreira D, Westman E, Eyjolfsdottir H, et al. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis. 2015;43:1059–72.PubMed
17.
18.
Aloe L, Levi-Montalcini R. Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons: effect of antiserum to nerve growth factor. Proc Natl Acad Sci U S A. 1979;76:1246–50.CrossRefPubMedPubMedCentral
19.
Unsicker K, Skaper SD, Varon S. Phenotypical changes of embryonic chick adrenal medullary cells in vitro induced by nerve growth factor and ciliary neuronotrophic factor. Neurosci Lett. 1985;60:127–32.CrossRefPubMed
20.
Angelucci F, Mathé AA, Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res. 2004;146:151–65.CrossRefPubMed
21.
Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19:514–20.CrossRefPubMed
22.
Levi-Montalcini R, Angeletti PU. Nerve growth factor. Physiol Rev. 1968;48:534–69.PubMed
23.
Dubanet L, Bentayeb H, Petit B, et al. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas. Br J Cancer. 2015;113:934–44.CrossRefPubMed
24.
Yaeger MJ, Koestner A, Marushige K, Marushige Y. The use of nerve growth factor as a reverse transforming agent for the treatment of neurogenic tumors: in vivo results. Acta Neuropathol. 1992;83:624–9.CrossRefPubMed
25.
Keles GE, Berger MS, Schofield D, Bothwell M. Nerve growth factor receptor expression in medulloblastomas and the potential role of the nerve growth factor as a differentiating agent in medulloblastomas cell lines. Neurosurgery. 1993;32:274–80.CrossRefPubMed
26.
Wadhwa S, Nag TC, Jindal A, et al. Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci. 2003;28:181–8.CrossRefPubMed
27.
Hamel W, Westphal M, Shepard HM. Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neurooncol. 1993;16:159–65.CrossRefPubMed
28.
Vinores SA, Koestner A. The effect of nerve growth factor on undifferentiated glioma cells. Cancer Lett. 1980;10:309–18.CrossRefPubMed
29.
Waris T, Rechardt L, Waris P. Differentiation of neuroblastoma cells induced by nerve growth factor in vitro. Experientia. 1973;29:1128–9.CrossRefPubMed
30.
Nakagawara A, Nakagawara AM, Scavarda NJ, et al. Association between high levels of expression of the trk gene and favourable outcome. N Engl J Med. 1993;328:847–54.CrossRefPubMed
31.
Antonelli A, Lenzi L, Nakagawara A, et al. Tumor suppressor proteins are differentially affected in human ependymoblastoma and medulloblastoma cells exposed to nerve growth factor. Cancer Invest. 2007;25:94–101.CrossRefPubMed
32.
Aloe L, Alleva E, Böhm A, Levi-Montalcini R. Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodstream. Proc Natl Acad Sci U S A. 1986;83:6184–7.CrossRefPubMedPubMedCentral
33.
Alleva E, Calamandrei G. On the functional role of polypeptide growth factors in rodent neurobehavioral development. Acta Neurobiol Exp. 1990;50:341–52.
34.
Arrighi N, Bodei S, Zani D, et al. Nerve growth factor signaling in prostate health and disease. Growth Factors. 2010;28:191–201.CrossRefPubMed
35.
Goda M, Atagi S, Amitani K, et al. Nerve growth factor suppresses prostate tumor growth. J Pharmacol Sci. 2010;112:463–6.CrossRefPubMed
36.
Singh A, Ruan Y, Tippett T, et al. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. J Exp Clin Cancer Res. 2015;34:104.CrossRefPubMedPubMedCentral
37.
Guerra B, Fischer M, Schaefer S, et al. The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment. J Exp Clin Cancer Res. 2015;34:125.CrossRefPubMedPubMedCentral
38.
Wu B, Sun C, Feng F, et al. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J Exp Clin Cancer Res. 2015;34:44.CrossRefPubMedPubMedCentral
39.
Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res. 2001;7:105–12.PubMed
40.
Zhang Y, Dang C, Ma Q, Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol Rep. 2005;14:161–71.PubMed
41.
Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci U S A. 1993;90:7961–5.CrossRefPubMedPubMedCentral
42.
Farina AR, Di Ianni N, Cappabianca L, et al. TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype. Biomed Res Int. 2013;2013:740187.PubMedPubMedCentral
43.
44.
Ødegaard E, Staff AC, Abeler VM, et al. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Hum Pathol. 2007;38:140–6.CrossRefPubMed
45.
Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976;73:2424–8.CrossRefPubMedPubMedCentral
46.
Chiaretti A, Falsini B, Servidei S, et al. Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. Neurorehabil Neural Repair. 2011;25:386–90.CrossRefPubMed
47.
48.
Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.CrossRefPubMed
49.
50.
51.
Mamidipudi V, Li X, Wooten MW. Identification of interleukin 1 receptor-associated kinase as a conserved component in the p75-neurotrophin receptor activation of nuclear factor-kappa B. J Biol Chem. 2002;277:28010–8.CrossRefPubMed
52.
Swenberg JA, Koestner A, Wechsler W, Denlinger RH. Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Res. 1972;32:2656–60.PubMed
53.
Raju NR, Koestner A, Marushige K, et al. Effect of nerve growth factor on the transplacental induction of neurinomas by ethylnitrosourea in Sprague–Dawley rats. Cancer Res. 1989;49:7120–3.PubMed
54.
Falsini B, Chiaretti A, Barone G, et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. Neurorehabil Neural Repair. 2011;25:512–20.CrossRefPubMed
55.
Kanaka-Gantenbein C, Dicou E, Czernichow P, Scharfmann R. Growth control of C6 glioma in vivo by nerve growth factor. J Neurooncol. 2002;59:199–205.CrossRef
56.
Micera A, Lambiase A, Stampachiacchiere B, et al. Nerve growth factor and tissue repair remodeling: trkA(NGFR) and p75(NTR), two receptors one fate. Cytokine Growth Factor Rev. 2007;18:245–56.CrossRefPubMed
57.
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.CrossRefPubMed
58.
59.
Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324–31.CrossRefPubMed
60.
Aloe L, Skaper SD, Leon A, Levi-Montalcini R. Nerve growth factor and autoimmune diseases. Autoimmunity. 1994;19:141–50.CrossRefPubMed
61.
Aloe L. The effect of nerve growth factor and its antibody on mast cells in vivo. J Neuroimmunol. 1988;18:1–12.CrossRefPubMed
62.
Bracci-Laudiero L, Aloe L, Buanne P, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol. 2002;123:58–65.CrossRefPubMed
63.
Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci U S A. 1989;86:10059–63.CrossRefPubMedPubMedCentral
64.
Brodie C, Gelfand EW. Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. J Immunol. 1992;148:3492–7.PubMed
65.
Torcia M, Bracci-Laudiero L, Lucibello M, et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell. 1996;85:345–56.CrossRefPubMed
66.
Solomon A, Aloe L, Pe'er J, et al. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol. 1998;102:454–60.CrossRefPubMed
67.
Lambiase A, Bracci-Laudiero L, Bonini S, et al. Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. Allergy Clin Immunol. 1997;100:408–14.CrossRef
68.
Lambiase A, Micera A, Sgrulletta R, et al. Nerve growth factor and the immune system: old and new concepts in the cross-talk between immune and resident cells during pathophysiological conditions. Curr Opin Allergy Clin Immunol. 2004;4:425–30.CrossRefPubMed
69.
Romon R, Adriaenssens E, Lagadec C, et al. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer. 2010;9:157.CrossRefPubMedPubMedCentral
70.
Molloy TJ, Devriese LA, Helgason HH, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer. 2011;104:1913–9.CrossRefPubMedPubMedCentral
71.
Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25:85–101.CrossRef
72.
73.
Aloe L, Alleva E, Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol Biochem Behav. 2002;73:159–66.CrossRefPubMed
74.
Maysinger D, Jalsenjak I, Cuello AC. Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions. Neurosci Lett. 1992;140:71–4.CrossRefPubMed
75.
Chen XQ, Fawcett JR, Rahman YE, et al. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J Alzheimers Dis. 1998;1:35–44.PubMed
76.
Bernabei R, Landi F, Bonini S, et al. Effect of topical application of nerve-growth factor on pressure ulcers. Lancet. 1999;354:307.CrossRefPubMed
77.
Tuveri M, Generini S, Matucci-Cerinic M, Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet. 2000;356:1739–40.CrossRefPubMed
78.
Generini S, Tuveri MA, Matucci Cerinic M, et al. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes. 2004;112:542–4.CrossRefPubMed
79.
Landi F, Aloe L, Russo A, et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med. 2003;139:635–41.CrossRefPubMed
80.
Aloe L, Calissano P, Levi-Montalcini R. Effects of oral administration of nerve growth factor and of its antiserum on sympathetic ganglia of neonatal mice. Brain Res. 1982;256:31–4.CrossRefPubMed
Metadata
Title
Nerve growth factor: role in growth, differentiation and controlling cancer cell development
Authors
Luigi Aloe
Maria Luisa Rocco
Bijorn Omar Balzamino
Alessandra Micera
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-016-0395-y

Other articles of this Issue 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Go to the issue

Research

Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I

Research

EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway

Research

TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway

Research

A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells

Research

FLIPL is critical for aerobic glycolysis in hepatocellular carcinoma

Research

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits